Objective: We aimed to clarify the drug interaction between tacrolimus and voriconazole and investigate the relationship between blood concentrations of tacrolimus and voriconazole in hematopoietic stem cell transplantation (HSCT) patients.
Materials And Methods: A retrospective study was conducted to investigate the relationship between blood concentration of tacrolimus and that of voriconazole at the Kindai University Nara Hospital. Patients who received HSCT and tacrolimus and were prescribed voriconazole for the prevention or treatment of aspergillosis from April 2010 to July 2018 were identified from the medical records. A total of 13 patients (administration route of tacrolimus: intravenously in 6 patients, orally in 7 patients) were enrolled in the present study.
Results: No significant correlation was observed between the blood concentration/dose (C/D) ratio of tacrolimus and the blood concentration of voriconazole (r = 0.38; p = 0.402; y = 102.8x + 928.1). However, a significant correlation was observed between the C/D ratio of tacrolimus and the blood concentration of voriconazole in the intravenous-administration group (r = 0.94; p = 0.0048; y = 421.9x + 810.5). Meanwhile, no significant correlation was observed in the oral-administration group (r = 0.43; p = 0.34; y = 7.9x + 719).
Conclusion: The C/D ratio of tacrolimus was significantly correlated with the blood concentration of voriconazole when tacrolimus was intravenously administered. There was a difference in the mechanism of drug interaction between tacrolimus and voriconazole depending on the administration routes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5414/CP203539 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus.
Lancet Oncol
November 2024
International Agency for Research on Cancer, Lyon, France; International Agency for Research on Cancer, Lyon, France.
Clinical drug interactions between voriconazole and 38 other drugs: a retrospective analysis of adverse events.
Front Pharmacol
September 2024
Department of Pharmacy, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing, China.
Article Synopsis
- Voriconazole (VRZ) has potential drug-drug interactions (DDIs) that can lead to adverse events (AEs), which this study aims to analyze using data from the OpenVigil FDA platform.
- The study specifically investigates AEs linked to VRZ interactions with proton pump inhibitors, NSAIDs, immunosuppressants, and other antibacterial drugs, using various statistical methods to evaluate these correlations.
- Out of 38 investigated drugs, 262 AEs were found, with 77 showing significant positive correlations with DDIs, notably highlighting graft-versus-host disease in immunosuppressant interactions and multiple organ dysfunction syndrome with other antibacterials, while also identifying sex and age differences in AEs.
External evaluation of tacrolimus population pharmacokinetic models in adult lung transplant patients: How to enhance the predictive ability of the model?
Int Immunopharmacol
December 2024
Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:
Purpose: Tacrolimus is the cornerstone of current immunosuppressive strategies after lung transplantation. However, its narrow therapeutic range and considerable pharmacokinetic variability pose challenges for individualized treatment. Several tacrolimus population pharmacokinetic (popPK) models have been developed for precision dosing in adult lung transplant patients.
View Article and Find Full Text PDFManagement of anti-melanoma differentiation-associated gene 5 antibody-induced refractory dermatomyositis complicated by interstitial pneumonia using tofacitinib and its outcomes: a case report.
J Med Case Rep
September 2024
Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, minami1-nishi16Chuo-Ku, Sapporo, Hokkaido, 060-8543, Japan.
Article Synopsis
- Clinical amyopathic dermatomyositis is a skin condition that lacks muscle symptoms and is often associated with anti-melanoma differentiation-associated gene 5 antibodies, particularly in Japanese patients, leading to poor outcomes in those with lung complications.
- A 52-year-old male presented with severe respiratory issues and skin rashes, diagnosed with dermatomyositis-related interstitial pneumonia, but treatment with steroids and immunosuppressants was largely ineffective.
- Despite some initial improvement after switching medications, the patient ultimately faced worsening respiratory failure due to invasive pulmonary aspergillosis, resulting in a fatal outcome.
Individualized dosing parameters for tacrolimus in the presence of voriconazole: a real-world PopPK study.
Front Pharmacol
September 2024
Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Article Synopsis
- A study was conducted on renal transplant recipients to understand how voriconazole affects tacrolimus levels, as there was no existing model for this interaction.
- The research involved 19 patients and used population pharmacokinetic analysis with blood samples to create a model showing how different factors, especially voriconazole levels and kidney function, affect tacrolimus dosing.
- The results indicated that tacrolimus dosage can be optimized based on voriconazole concentration and serum creatinine, with voriconazole having a stronger impact on tacrolimus levels.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!